Outsourcing

Jun 01, 2018
By BioPharm International Editors
Catalent’s GPEx technology was used to develop antibody for anti-methamphetamine clinical study.
Jun 01, 2018
By BioPharm International Editors
TxCell announces manufacturing agreement with Lonza for its HLA-A2 CAR-Treg cellular product.
May 30, 2018
By BioPharm International Editors
GE Healthcare and the Centre for Commercialization of Regenerative Medicine (CCRM) will support scale-up efforts by DiscGenics for a new cell therapy intended to treat back pain.
May 24, 2018
By BioPharm International Editors
In adding a Vanrx Pharmasystems aseptic filling isolator, FUJIFILM adds fill/finish for gene therapies and viral vaccines.
May 17, 2018
By BioPharm International Editors
The second phase of a $5.5-million expansion adds controlled-substance and controlled-temperature storage to Catalent clinical trials facility.
May 16, 2018
By BioPharm International Editors
Valerius Biopharma will use Catalent’s GPEx technology to produce cell lines for biosimilar drugs.
May 10, 2018
By BioPharm International Editors
The companies have extended a contract agreement for the commercial manufacture of the active pharmaceutical ingredient for vonapanitase, an investigational drug intended to improve hemodialysis vascular access outcomes.
May 07, 2018
By BioPharm International Editors
Lonza announces addition of mid-scale biologics manufacturing capacity and cell-therapy suites at Portsmouth, NH site.
May 03, 2018
By BioPharm International Editors
The company has begun expansion efforts for its process-development capabilities and laboratory infrastructure.
May 01, 2018
BioPharm International
CDMOs can claim credit for the robust growth of emerging bio/pharma financings.
native1_300x100
lorem ipsum